CD19 and acute lymphoblastic leukemia: Blinatumomab, a CD19/CD3 BiTE, has been successfully applied to treat acute lymphoblastic leukemia and shows significant clinical benefits, though it needs continuous intravenous infusion due to its short half-life [47].